VISCHER has advised Nuclidium AG. Walder Wyss has advised Angelini Ventures, Kurma Partners, and Wellington Partners as co-lead investors. Nuclidium AG, a clinical-stage radiopharmaceutical company, has...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised RhyGaze AG on the deal. RhyGaze, a biotechnology company based in Basel and Philadelphia has secured a Series A financing of USD 86...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Alentis Therapeutics on the deal. Honigman advised Catalio Capital Management. Alentis Therapeutics raised $181.4 million in Series D financing, supported by a syndicate...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised SixPeaks Bio AG while Lenz & Staehelin acted as Swiss counsel to AstraZeneca. SixPeaks Bio AG has secured USD30 million in Series A...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Axalta Coating Systems on this transaction. Axalta Coating Systems Group (NYSE: AXTA) acquired André Koch AG, an established provider of car repair and...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Boehringer Ingelheim in the transaction. Boehringer Ingelheim announced the acquisition of privately-held T3 Pharmaceuticals AG, a clinical stage Swiss biotech company, for an...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
You must be a Standard 1 Year member to access this content.
Walder Wyss advises Alentis Therapeutics on the financing. Alentis Therapeutics has announced $105 million in Series C financing. The funding round was led by Jeito Capital...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised BC Platforms on the deal. BC Platforms announced a USD 20m growth financing led by Jolt Capital. BC Platforms is a global leader in...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
You must be a Standard 1 Year member to access this content.
MLLStart! advised Clinical Research Ventures. Walder Wyss advises BioVersys. BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for...
You must be a Standard 1 Year member to access this content.
